Description
Crystagen is a synthetic short tripeptide bioregulator composed of three amino acids—glutamic acid, aspartic acid, and proline (Glu-Asp-Pro)—developed within the Khavinson bioregulation program at the St. Petersburg Institute of Bioregulation and Gerontology. [1]
Key Characteristics & Mechanism
- Classification: It is classified as an immune and thymic-directed short signaling peptide. [1, 2]
- Function: In Russian preclinical and clinical literature, it is studied for its ability to interact with DNA-specific binding sites, regulate gene expression in immune and thymic cells, and help normalize immune function against age-related decline (immunosenescence) or viral/infectious stressors. [1, 2, 3]
- Forms Available: It is distributed in capsule form, sublingual sprays (Lingual), or lyophilized powder/vials intended for research. [1, 2, 3]
- Regulatory Status: Crystagen is not approved by the U.S. Food and Drug Administration (FDA) for the treatment or prevention of any medical condition and is primarily handled as a research compound.
Reviews
There are no reviews yet.